BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25672620)

  • 21. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
    Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
    Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
    Hagmann W; Jesnowski R; Löhr JM
    Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice.
    Zheng X; Cui XX; Gao Z; Verano M; Huang MT; Liu Y; Rabson AB; Conney AH
    Int J Oncol; 2012 Dec; 41(6):2269-75. PubMed ID: 23041978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
    Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
    Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
    Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
    Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells.
    Hu H; Gu Y; Qian Y; Hu B; Zhu C; Wang G; Li J
    Biochem Biophys Res Commun; 2014 Sep; 452(1):106-11. PubMed ID: 25152407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells.
    Kaur M; Deep G; Jain AK; Raina K; Agarwal C; Wempe MF; Agarwal R
    Carcinogenesis; 2013 Jul; 34(7):1585-92. PubMed ID: 23475945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
    Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
    Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
    Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
    Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
    Miyake T; Honma Y; Urano T; Kato N; Suzumiya J
    Int J Oncol; 2015 Jul; 47(1):315-24. PubMed ID: 25936828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
    Gu J; Huang W; Wang X; Zhang J; Tao T; Zheng Y; Liu S; Yang J; Chen ZS; Cai CY; Li J; Wang H; Fan Y
    Mol Cancer; 2022 May; 21(1):112. PubMed ID: 35538494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer.
    Lee SH; Hwang HK; Lee WJ; Kang CM
    Cell Oncol (Dordr); 2021 Dec; 44(6):1363-1371. PubMed ID: 34791637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
    Wang C; Huang H
    Biochem Biophys Res Commun; 2021 Nov; 579():181-187. PubMed ID: 34624736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
    Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bitter melon juice-intake modulates glucose metabolism and lactate efflux in tumors in its efficacy against pancreatic cancer.
    Dhar D; Raina K; Kant R; Wempe MF; Serkova NJ; Agarwal C; Agarwal R
    Carcinogenesis; 2019 Sep; 40(9):1164-1176. PubMed ID: 31194859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines.
    Takezaki Y; Namikawa T; Koyama T; Munekage E; Munekage M; Maeda H; Kitagawa H; Hanazaki K
    Anticancer Res; 2016 Nov; 36(11):6077-6082. PubMed ID: 27793935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
    Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
    BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
    Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
    Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
    Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
    J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.